Full-Time
Senior Mechanical Engineer
Posted on 8/21/2026
Zeiss
1,001-5,000 employees
Corporate venture capital for deep-tech startups
No salary listed
Oberkochen, Germany
In Person
International travel is required.
Bachelor's
 Mechanical Engineering (1) |
|---|
Get referred to Zeiss
See people who can refer or advise you
- An above-average degree in mechanical engineering, mechatronics engineering, physics, or a comparable technical degree.
- Experience developing highly complex mechatronic systems, including knowledge of structural system mechanics and measurement technology such as electron microscopy.
- Proven experience in system dynamics, including finite element method, modal analysis, and practical analysis on machines.
- Knowledge and skills to design complex systems using suitable modeling and simulation methods.
- Ability to manage uncertainty in a rapidly changing environment.
- Collaboration and conflict-resolution skills.
- Willingness to travel abroad for work.
- Excellent oral and written communication skills in English.
- Design and develop mechanical and electromechanical modules for metrology tools while meeting functionality, manufacturability, regulatory, and economic specifications.
- Own the structural design of modules and system interfaces as a member of an international project team.
- Participate in development projects with internal and external partners and take responsibility for sub-projects.
- Break down system specifications into requirements and align them with other research and development stakeholders.
- Test prototypes in the laboratory or cleanroom and create technical documentation to ensure product performance.
- Document and manage technical data, including product requirement documents and material master data.
- Further training and/or certification in system dynamics.
- Experience with Ansys, Python, design of experiments, and failure mode and effects analysis.
- German language skills.
ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$67.7M
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS led Maculaser's May 2026 round for retinal laser therapy commercialization.
- ZEISS Ventures led SeeTrue's €2.2 million round on August 6, 2026.
- ZEISS launched ClearMind lenses and DuraVision Plus in January 2026, reinforcing optical leadership.
What critics are saying
- Carl Zeiss Meditec cut 2026 revenue 5.7% and targets 1,000 job reductions.
- ZEISS's 2026 restructuring threatens innovation velocity and employee morale through 2028/29.
- A prolonged MedTech slump or failed turnaround would weaken ZEISS Ventures' strategic value.
What makes Zeiss unique
- ZEISS Ventures pairs capital with ZEISS distribution, engineering, and ophthalmology channels.
- Its 2026 deals target eye health, imaging, and optoelectronics adjacencies.
- ZEISS brand credibility de-risks pilots for startups selling into regulated healthcare.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Company News
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.
ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.
ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.
ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.